• Explore /
  • Poster
  • / Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Mark Christopher Markowski

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Mark Christopher Markowski , Deepak Kilari , Mario A. Eisenberger , Rana R. McKay , Robert Dreicer , Mohit Trikha , Elisabeth I. Heath , Jing Li , Pamela D. Garzone , Travis S. Young

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04077021

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS5094)

DOI

10.1200/JCO.2021.39.15_suppl.TPS5094

Abstract #

TPS5094

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jones T. Nauseef

First Author: Daniel Peter Petrylak

First Author: Daniel Peter Petrylak

First Author: Shahneen Sandhu